<!-- CoverPageHeader start -->
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
<TITLE> TransEnterix, Inc. (Form: 8-K) </TITLE>
</HEAD>
<BODY TEXT="#000000" BGCOLOR="#FFFFFF" ALINK="#0000FF" HLINK="#FF0000" VLINK="#800080">
<!-- Comment1 -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<P>
<!-- CoverPageHeader end --><!-- CoverPageTitle START -->
<A NAME="DOCUMENT_TOP">&nbsp;</A>
<HR NOSHADE>
<P>
<P ALIGN="CENTER">
<FONT SIZE="4">
		UNITED STATES<BR>
	SECURITIES AND EXCHANGE COMMISSION
</FONT>
<BR>
<FONT SIZE="2">
	WASHINGTON, D.C. 20549
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="5">
	FORM 8-K
</FONT>
<FONT SIZE="2">

</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="3">
	CURRENT REPORT
</FONT>
</P>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934
</FONT>
</P>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Date of Report (Date of Earliest Event Reported):
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	August 14, 2015
</FONT>
</TD>
</TR>
</TABLE>
<BR>
</CENTER>
<!-- CoverPageTitle END --><!-- CoverPageRegistrant START -->
<P ALIGN="CENTER"><!-- -->
<FONT SIZE="6">
	TransEnterix, Inc.
</FONT>
<FONT SIZE="2">
<BR>__________________________________________<BR>
	(Exact name of registrant as specified in its charter)
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="33%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="33%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Delaware
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	0-19437
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	11-2962080
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________________<BR>
	(State or other jurisdiction
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_____________<BR>
	(Commission
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
______________<BR>
	(I.R.S. Employer
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	of incorporation)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	File Number)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Identification No.)
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	635 Davis Drive, Suite 300, Morrisville, North Carolina
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	27560
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
_________________________________<BR>
	(Address of principal executive offices)
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
___________<BR>
	(Zip Code)
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">

<TR VALIGN="BOTTOM">
<TD WIDTH="51%">
	&nbsp;
</TD>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="44%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	Registrant&#146;s telephone number, including area code:
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<FONT SIZE="2">
	919-765-8400
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<P ALIGN="CENTER">
<FONT SIZE="2">
	Not Applicable
<BR>______________________________________________<BR>
	Former name or former address, if changed since last report
</FONT>
<P ALIGN="CENTER">
<FONT SIZE="2">
	&nbsp;
</FONT>
<!-- CoverPageRegistrant END --><P><FONT SIZE="2">
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:</FONT>
</P>
<P><FONT SIZE="2">
[&nbsp;&nbsp;]&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<br>
[&nbsp;&nbsp;]&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<br>
</P></FONT><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END -->



<P align="left" style="font-size: 10pt"><FONT style="font-size: 12pt"><B>Item&nbsp;1.01 Entry into a Material Definitive Agreement.</B>
</FONT>

<P align="left" style="font-size: 12pt">On August&nbsp;14, 2015, TransEnterix, Inc. (the &#147;Company&#148;) and its operating subsidiaries entered into
the first amendment (the &#147;First Amendment&#148;) to the amended and restated loan and security
agreement, dated September&nbsp;26, 2014 (the &#147;A&R Loan Agreement,&#148; and together with the First
Amendment, the &#147;Loan Agreement&#148;) with Silicon Valley Bank, as Lender and Oxford Finance LLC, as
Lender and Collateral Agent (collectively, the &#147;Lenders&#148;). The First Amendment increases the second
tranche from $5,000,000 to $10,000,000 and increases the commitment of the Lenders to make certain
term loans to the Company from an aggregate principal amount of up to $25,000,000, under the A&R
Loan Agreement, to an aggregate principal amount of up to $30,000,000. The second tranche adds to
the outstanding principal amount of the existing term loan, which is currently $10,000,000,
borrowed by the Company from the Lenders under the A&R Loan Agreement, for an aggregate of
$20,000,000 in borrowings as of August&nbsp;14, 2015. The First Amendment also modifies certain terms
related to the third tranche of $10,000,000. Further, the First Amendment modifies the period in
which the Company can make interest-only payments on the term loans until May&nbsp;1, 2016, which
interest-only period is extended to November&nbsp;1, 2016 if the Company receives 510(k) clearance for
its SurgiBot system at any time prior to April&nbsp;30, 2016. The First Amendment extends the maturity
date of the term loans from April&nbsp;1, 2018 to October&nbsp;1, 2018 without the interest-only extension
and from October&nbsp;1, 2018 until April&nbsp;1, 2019 with the interest-only extension.


<P align="left" style="font-size: 12pt">The term loans bear interest at a fixed rate equal to 7.50% per annum, subject to adjustment at
funding for subsequent tranches on an increase in LIBOR above a designated rate. The term loans
will be required to be prepaid if the term loans are accelerated following an event of default. In
addition, the Company is permitted to prepay the term loans in full at any time upon 10&nbsp;days&#146;
written notice to the Lenders. Upon the earliest to occur of the maturity date, acceleration of
the term loans, or prepayment of a term loan, the Company is required to make a final payment equal
to the original principal amount of each term loan multiplied by 6.50% without the interest-only
extension or 8.00% with the interest-only extension (the &#147;Final Payment Fee&#148;). Any prepayment,
whether mandatory or voluntary, must include the Final Payment Fee, interest at the default rate
(which is the rate otherwise applicable plus 5%) with respect to any amounts past due, and the
Lenders&#146; expenses and all other obligations that are due and payable to the Lenders.


<P align="left" style="font-size: 12pt">In connection with the entry into the Loan Agreement, the Company became obligated to make a
payment equal to the unaccrued portion of the final payment due under the Original Loan Agreement,
the accrued portion of the final payment as of the effective date of the Loan Agreement (which will
not reduce the Final Payment Fee), plus a facility fee payment of $90,000. In addition, in
connection with the second tranche borrowings, the Company issued warrants to the Lenders to
purchase shares of the Company&#146;s common stock. Additional warrants will be issued if additional
tranche term loans are made under the Loan Agreement. The warrants expire seven years from their
respective issue date.


<P align="left" style="font-size: 12pt">The Loan Agreement is secured by a security interest in assets of the Company and its current and
future subsidiaries, including a security interest in intellectual property proceeds, but excluding
a current security interest in intellectual property. The Loan Agreement contains customary
representations (tested on a continual basis) and covenants that, subject to exceptions, restrict
the Company&#146;s ability to do the following things: declare dividends or redeem or repurchase equity
interests; incur additional liens; make loans and investments; incur additional indebtedness;
engage in mergers, acquisitions, and asset sales; transact with affiliates; undergo a change in
control; add or change business locations; and engage in businesses that are not related to its
existing business.


<P align="left" style="font-size: 12pt">The foregoing is a summary of the Loan Agreement and the warrants and is qualified in its entirety
by reference to the complete text of the First Amendment and the form of Warrant to Purchase Common
Stock, which are filed as Exhibits 10.1 and 4.1, respectively to this Current Report on Form 8-K
and incorporated by reference herein.


<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 12pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right"><B>Item&nbsp;2.03</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet
Arrangement of a Registrant.</B></TD>
</TR>

</TABLE>


<P align="left" style="font-size: 12pt">The information disclosed under Item&nbsp;1.01 of this Current Report on Form 8-K is incorporated by
reference under this Item&nbsp;2.03.


<P align="left" style="font-size: 12pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits.</B>


<P align="left" style="font-size: 12pt"><B>(d)</B>

<DIV align="center">
<TABLE style="font-size: 12pt" cellspacing="0" border="0" cellpadding="0" width="95%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="92%">&nbsp;</TD>
</TR>
<TR style="font-size: 12pt" valign="bottom">
    <TD nowrap align="center" colspan="3" style="border-bottom: 1px solid #000000">Exhibit &nbsp;&nbsp;No.&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Description</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="font-size: 12pt">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">4.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Form of Warrant to Purchase Common Stock for warrants issued<BR>
to the Lenders (incorporated by reference to Exhibit&nbsp;4.1 to<BR>
the Company&#146;s Current Report on Form&nbsp;8-K dated September&nbsp;26,<BR>
2014).</DIV></TD>
</TR>
<TR valign="bottom" style="font-size: 12pt">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">10.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">First Amendment to Amended and Restated Loan and Security<BR>
Agreement, dated August&nbsp;14, 2015, by and among TransEnterix,<BR>
Inc., TransEnterix Surgical, Inc. and SafeStitch LLC, as<BR>
Borrower, and Oxford Finance LLC, as Lender and Collateral<BR>
Agent, and Silicon Valley Bank, as Lender.</DIV></TD>
</TR>
<TR valign="bottom" style="font-size: 12pt">
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">99.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Press release issued by the Company dated August&nbsp;17, 2015.</DIV></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt; display: none">




<!-- v.121908 -->

<!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><!-- SignatureHeader START -->
<P ALIGN="CENTER">
<FONT SIZE="2">
<B>
	SIGNATURES
</B>
</FONT>
</P>
<P ALIGN="LEFT">
<FONT SIZE="2">
	Pursuant to the requirements of the Securities Exchange Act of 1934, the
	registrant has duly caused this report to be signed on its behalf by the
	undersigned hereunto duly authorized.
</FONT>
</P>
<!-- SignatureHeader END --><!-- Signature START -->
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="100%">
<TR VALIGN="BOTTOM">
<TD WIDTH="19%">
	&nbsp;
</TD>
<TD WIDTH="34%">
	&nbsp;
</TD>
<TD WIDTH="3%">
	&nbsp;
</TD>
<TD WIDTH="1%">
	&nbsp;
</TD>
<TD WIDTH="43%">
	&nbsp;
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD COLSPAN="3" VALIGN="TOP" ALIGN="LEFT">
<FONT SIZE="2">
	TransEnterix, Inc.
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
<I>
	August 17, 2015
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	By:
</I>
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Joseph P. Slattery
</I>
<BR>
</FONT>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<HR SIZE="1" NOSHADE>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Name: Joseph P. Slattery
</I>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD>
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<FONT SIZE="2">
<I>
	Title: EVP and CFO
</I>
</FONT>
</TD>
</TR>
</TABLE>
</CENTER>
<!-- Signature END --><!-- PageBreak START -->
<P>
<HR NOSHADE>
<DIV ALIGN="LEFT" STYLE="PAGE-BREAK-BEFORE:ALWAYS">
<A HREF="#DOCUMENT_TOP">
<U>
<B>
<FONT SIZE="2">Top of the Form</FONT>
</B>
</U>
</A>
</DIV>
<!-- PageBreak END --><P ALIGN="CENTER">
<FONT SIZE="2">
	Exhibit&nbsp;Index
</FONT>
<CENTER>
<TABLE CELLSPACING="0" BORDER="0" CELLPADDING="0" WIDTH="60%">
<TR VALIGN="BOTTOM">
<TD WIDTH="8%">
	&nbsp;
</TD>
<TD WIDTH="15%">
	&nbsp;
</TD>
<TD WIDTH="77%">
	&nbsp;
</TD>
</TR>

<BR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Exhibit No.
</B>
</FONT>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="LEFT">
<FONT SIZE="1">
<B>
	Description
</B>
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD NOWRAP ALIGN="CENTER">
<HR SIZE="1" NOSHADE>
</TD>
<TD>
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD NOWRAP ALIGN="CENTER">
<HR ALIGN="LEFT" SIZE="1" WIDTH="88%" NOSHADE>
</TD>
</TR>





<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" WIDTH="8%" nowrap>
<FONT SIZE="2">
<DIV ALIGN="LEFT">
	10.1
</DIV>
</FONT>
</TD>
<TD WIDTH="15%">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
<FONT SIZE="2">
First Amendment to Amended and Restated Loan and Security Agreement, dated August 14, 2015, by and among TransEnterix, Inc., TransEnterix Surgical, Inc. and SafeStitch LLC, as Borrower, and Oxford Finance LLC, as Lender and Collateral Agent, and Silicon Valley Bank, as Lender
</FONT>
</TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" WIDTH="8%" nowrap>
<FONT SIZE="2">
<DIV ALIGN="LEFT">
	99.1
</DIV>
</FONT>
</TD>
<TD WIDTH="15%">
<FONT SIZE="2">
	&nbsp;
</FONT>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP" WIDTH="77%">
<FONT SIZE="2">
Press release issued by the Company dated August 17, 2015
</FONT>
</TD>
</TR></TABLE></CENTER><!-- HTMLFooter START -->
</BODY>
</HTML>
<!-- HTMLFooter END -->
[{"type": "8-K", "sequence": "1", "filename": "htm_52305.htm", "description": "LIVE FILING", "secsgml_size_bytes": 17687}]
{"company-data": {"conformed-name": "TRANSENTERIX INC.", "cik": "0000876378", "assigned-sic": "3841", "irs-number": "112962080", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-19437", "film-number": "151057788"}, "business-address": {"street1": "635 DAVIS DRIVE", "street2": "SUITE 300", "city": "MORRISVILLE", "state": "NC", "zip": "27560", "phone": "919-765-8400"}, "mail-address": {"street1": "635 DAVIS DRIVE", "street2": "SUITE 300", "city": "MORRISVILLE", "state": "NC", "zip": "27560"}, "former-company": [{"former-conformed-name": "SafeStitch Medical, Inc.", "date-changed": "20080211"}, {"former-conformed-name": "CELLULAR TECHNICAL SERVICES CO INC", "date-changed": "19930328"}]}
TransEnterix, Inc. (Form: 8-K)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
August 14, 2015
TransEnterix, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
Delaware
0-19437
11-2962080
_____________________
(State or other jurisdiction
_____________
(Commission
______________
(I.R.S. Employer
of incorporation)
File Number)
Identification No.)
635 Davis Drive, Suite 300, Morrisville, North Carolina
27560
_________________________________
(Address of principal executive offices)
___________
(Zip Code)
Registrant's telephone number, including area code:
919-765-8400
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Top of the Form
Item 1.01 Entry into a Material Definitive Agreement.
On August 14, 2015, TransEnterix, Inc. (the "Company") and its operating subsidiaries entered into
the first amendment (the "First Amendment") to the amended and restated loan and security
agreement, dated September 26, 2014 (the "A&R Loan Agreement," and together with the First
Amendment, the "Loan Agreement") with Silicon Valley Bank, as Lender and Oxford Finance LLC, as
Lender and Collateral Agent (collectively, the "Lenders"). The First Amendment increases the second
tranche from $5,000,000 to $10,000,000 and increases the commitment of the Lenders to make certain
term loans to the Company from an aggregate principal amount of up to $25,000,000, under the A&R
Loan Agreement, to an aggregate principal amount of up to $30,000,000. The second tranche adds to
the outstanding principal amount of the existing term loan, which is currently $10,000,000,
borrowed by the Company from the Lenders under the A&R Loan Agreement, for an aggregate of
$20,000,000 in borrowings as of August 14, 2015. The First Amendment also modifies certain terms
related to the third tranche of $10,000,000. Further, the First Amendment modifies the period in
which the Company can make interest-only payments on the term loans until May 1, 2016, which
interest-only period is extended to November 1, 2016 if the Company receives 510(k) clearance for
its SurgiBot system at any time prior to April 30, 2016. The First Amendment extends the maturity
date of the term loans from April 1, 2018 to October 1, 2018 without the interest-only extension
and from October 1, 2018 until April 1, 2019 with the interest-only extension.
The term loans bear interest at a fixed rate equal to 7.50% per annum, subject to adjustment at
funding for subsequent tranches on an increase in LIBOR above a designated rate. The term loans
will be required to be prepaid if the term loans are accelerated following an event of default. In
addition, the Company is permitted to prepay the term loans in full at any time upon 10 days'
written notice to the Lenders. Upon the earliest to occur of the maturity date, acceleration of
the term loans, or prepayment of a term loan, the Company is required to make a final payment equal
to the original principal amount of each term loan multiplied by 6.50% without the interest-only
extension or 8.00% with the interest-only extension (the "Final Payment Fee"). Any prepayment,
whether mandatory or voluntary, must include the Final Payment Fee, interest at the default rate
(which is the rate otherwise applicable plus 5%) with respect to any amounts past due, and the
Lenders' expenses and all other obligations that are due and payable to the Lenders.
In connection with the entry into the Loan Agreement, the Company became obligated to make a
payment equal to the unaccrued portion of the final payment due under the Original Loan Agreement,
the accrued portion of the final payment as of the effective date of the Loan Agreement (which will
not reduce the Final Payment Fee), plus a facility fee payment of $90,000. In addition, in
connection with the second tranche borrowings, the Company issued warrants to the Lenders to
purchase shares of the Company's common stock. Additional warrants will be issued if additional
tranche term loans are made under the Loan Agreement. The warrants expire seven years from their
respective issue date.
The Loan Agreement is secured by a security interest in assets of the Company and its current and
future subsidiaries, including a security interest in intellectual property proceeds, but excluding
a current security interest in intellectual property. The Loan Agreement contains customary
representations (tested on a continual basis) and covenants that, subject to exceptions, restrict
the Company's ability to do the following things: declare dividends or redeem or repurchase equity
interests; incur additional liens; make loans and investments; incur additional indebtedness;
engage in mergers, acquisitions, and asset sales; transact with affiliates; undergo a change in
control; add or change business locations; and engage in businesses that are not related to its
existing business.
The foregoing is a summary of the Loan Agreement and the warrants and is qualified in its entirety
by reference to the complete text of the First Amendment and the form of Warrant to Purchase Common
Stock, which are filed as Exhibits 10.1 and 4.1, respectively to this Current Report on Form 8-K
and incorporated by reference herein.
Item 2.03
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet
Arrangement of a Registrant.
The information disclosed under Item 1.01 of this Current Report on Form 8-K is incorporated by
reference under this Item 2.03.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibit   No.
Description
4.1
Form of Warrant to Purchase Common Stock for warrants issued
to the Lenders (incorporated by reference to Exhibit 4.1 to
the Company's Current Report on Form 8-K dated September 26,
2014).
10.1
First Amendment to Amended and Restated Loan and Security
Agreement, dated August 14, 2015, by and among TransEnterix,
Inc., TransEnterix Surgical, Inc. and SafeStitch LLC, as
Borrower, and Oxford Finance LLC, as Lender and Collateral
Agent, and Silicon Valley Bank, as Lender.
99.1
Press release issued by the Company dated August 17, 2015.
Top of the Form
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
	registrant has duly caused this report to be signed on its behalf by the
	undersigned hereunto duly authorized.
TransEnterix, Inc.
August 17, 2015
By:
Joseph P. Slattery
Name: Joseph P. Slattery
Title: EVP and CFO
Top of the Form
Exhibit Index
Exhibit No.
Description
10.1
First Amendment to Amended and Restated Loan and Security Agreement, dated August 14, 2015, by and among TransEnterix, Inc., TransEnterix Surgical, Inc. and SafeStitch LLC, as Borrower, and Oxford Finance LLC, as Lender and Collateral Agent, and Silicon Valley Bank, as Lender
99.1
Press release issued by the Company dated August 17, 2015